(Q34076431)

30 July 2017

The role of TNF inhibitors in psoriasis therapy: new implications for associated comorbidities (English)

1 reference

30 July 2017

0 references

1 reference

John Yost

1

1 reference

PubMed ID

20948750

30 July 2017

Johann E Gudjonsson

series ordinal

2

1 reference

30 July 2017

8 May 2009

1 reference

30 July 2017

F1000 medicine reports

1 reference

30 July 2017

1

1 reference

30 July 2017

1399-1405

1 reference

Long-term data in the treatment of psoriasis

30 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924720

Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924720

Psoriasis and metabolic disease: epidemiology and pathophysiology

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924720

National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924720

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924720

The effect of weight on the efficacy of biologic therapy in patients with psoriasis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924720

Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924720

TNF-alpha and adipocyte biology

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924720

Biologic therapies in psoriasis: a new therapeutic approach

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924720

Mechanisms of action of etanercept in psoriasis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924720

Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924720

Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924720

Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924720

The risk of mortality in patients with psoriasis: results from a population-based study

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924720

Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924720

Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924720

Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2924720

Three years' experience with infliximab in recalcitrant psoriasis

28 October 2018

1 reference

12 December 2020

The Risk of Lymphoma in Patients with Psoriasis

1 reference

12 December 2020

Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis

1 reference

12 December 2020

Etanercept Treatment for Children and Adolescents with Plaque Psoriasis

1 reference

12 December 2020

TNF Inhibition Rapidly Down-Regulates Multiple Proinflammatory Pathways in Psoriasis Plaques

1 reference

12 December 2020

Addition of low-dose methotrexate to infliximab in the treatment of a patient with severe, recalcitrant pustular psoriasis

1 reference

12 December 2020

Risk of Myocardial Infarction in Patients With Psoriasis

1 reference

12 December 2020

British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005

1 reference

12 December 2020

Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis

1 reference

12 December 2020

Identifiers

DOI

10.3410/M1-30

1 reference

30 July 2017

1 reference

30 July 2017

1 reference

PubMed ID

20948750